Clinical Trial Update: Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating midostaurin added to standard chemotherapy for newly diagnosed FLT3-mutated acute myeloid leukemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Midostaurin (midostaurin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Myeloid Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2024-02-08